06/05/2026 InflaRx announced advancement of Izicopan in AAV and select renal diseases SynAct Pharma completed dosing for the last patient in Phase 2b study for RA InflaRx announced advancement of Izicopan in AAV and select renal diseases (Ref) InflaRx announced that it intended to develop izicopan (an oral C5a receptor inhibitor) in ANCA-Associated Vasculitis (AAV). InflaRx was conducting Phase 2 planning for izicopan in AAV and was evaluating the feasibility of multiple deve

05/05/2026 J&J announced Phase 2b data from two studies in IBD J&J announced Phase 3 results for guselkumab in CD Avalo Therapeutics announced positive Phase 2 results for abdakibart in HS J&J announced Phase 2b data from two studies in IBD (Ref) Johnson & Johnson announced data from two Phase 2b studies, DUET-UC/ NCT05242484 and DUET-CD/ NCT05242471, which evaluated JNJ-4804 (IL-23 and TNF-α) in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s

04/05/2026 Mirum Pharmaceuticals’ Volixibat met its primary endpoint in a Phase 2b study in Patients with PSC Mirum Pharmaceuticals’ Volixibat met its primary endpoint in a Phase 2b study in Patients with PSC (Ref) Mirum Pharmaceuticals announced that the primary endpoint was met in the Phase 2b, VISTAS study, which evaluated volixibat (an IBAT inhibitor) in patients with primary sclerosong cholangitis (PSC). Volixibat demonstrated a statistically significant and clinically m

20/04/2026 Nektar Therapeutics announced results from Phase 2b study for rezpegaldesleukin in severe-to-very severe AA Biogen entered into agreement with TJ Biopharma for felzartamab in the Greater China Region Nektar Therapeutics announced results from Phase 2b study for rezpegaldesleukin in severe-to-very severe AA ( Ref ) Nektar Therapeutics announced topline results from its Phase 2b REZOLVE-AA/ NCT06340360 study, which evaluated rezpegaldesleukin (IL-2 pathway agonist) f

17/02/2026 Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD Nektar Therapeutics announced a research collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD ( Ref ) Sanofi and Teva announced positive results from the Phase 2b RELIEVE UCCD LTE/NCT05668013 study of